The global IBD drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of IBD, rising awareness about the disease and its treatment options, and technological advancements in drug development.
The global IBD drugs market is segmented on the basis of type into preface, eluxadoline, alosetron, rifaximin, loperamide, diphenoxylate + atropine (DPA), dicyclomine and hyoscyamine (DH). Preface segment accounted for the largest share in 2018 owing to its wide range of applications such as prophylaxis against NSAID-induced ulcers and prevention of NSAID-induced gastric ulcers. Eluxadoline was the fastest growing type in 2018 due to its efficacy in treating diarrhea-predominant IBS patients with moderate or severe symptoms who have not responded well to other treatments. Alosetron was also among the fastest growing types owing to its efficacy in treating women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded well to other treatments. Rifaximin was also among the fastest growing types owing to its efficacy in treating travelers’ diarrhea caused by bacterial infections that are resistant or difficult for antibiotics like ciprofloxacin or azithromycin. Loperamide was also among the fastest growing types owing to its efficacy as an over-the counter medication for short term relief from acute diarrhea episodes associated with viral gastroenteritis or food poisoning caused by bacteria like Salmonella typhi or Campylobacter jejuni which are resistant against antibiotics like ciprofloxacin or azithromycin respectively. Diphenoxylate + atropine (DPA) accounted for a significant share due mainly because it has been used extensively since 1970s for managing chronic constipation and irritable bowel syndrome with constipation (IBSC). Dicyclomine accounted for a significant share due mainly because it has been used extensively since 1970s for managing chronic constipation and irritable bowel syndrome with constipation (IBSC). DH accounted only 0% share globally but it is expected that this will increase significantly during forecast period due mainly because DH has been found effective against abdominal pain associated with functional gastrointestinal disorders such as irritable bowel syndrome without constipation (IBSW), functional dyspepsia etc, which are common conditions seen across all age groups including children below 12 years old.
-IBS-D is a chronic condition that affects the large intestine and causes abdominal pain, cramping, bloating, gas, diarrhea and constipation.
-The global IBS-D drugs market is expected to grow at a CAGR of 4.5% from 2017 to 2025.
-The global IBS-D drugs market is expected to reach USD 3.2 billion by 2025 from USD 2.4 billion in 2017 with an estimated growth of 4.5%.
Industry Growth Insights published a new data on “Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market”. The research report is titled “Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market research by Types (Preface, Eluxadoline, Alosetron, Rifaximin, Loperamide, Diphenoxylate + Atropine, Dicyclomine and Hyoscyamine), By Applications (Hospitals, Clinics, Others), By Players/Companies Astellas Pharmaceuticals, Actavis, Pfizer, GlaxoSmithKline, Salix Pharmaceuticals Ltd, AstraZenenca”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report
By Type
Preface, Eluxadoline, Alosetron, Rifaximin, Loperamide, Diphenoxylate + Atropine, Dicyclomine and Hyoscyamine
By Application
Hospitals, Clinics, Others
By Companies
Astellas Pharmaceuticals, Actavis, Pfizer, GlaxoSmithKline, Salix Pharmaceuticals Ltd, AstraZenenca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
 Drugs Industry Outlook.svg)
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report Segments:
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented on the basis of:
Types
Preface, Eluxadoline, Alosetron, Rifaximin, Loperamide, Diphenoxylate + Atropine, Dicyclomine and Hyoscyamine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharmaceuticals
- Actavis
- Pfizer
- GlaxoSmithKline
- Salix Pharmaceuticals Ltd
- AstraZenenca
 Drugs Market Overview.svg)
Highlights of The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Preface
- Eluxadoline
- Alosetron
- Rifaximin
- Loperamide
- Diphenoxylate + Atropine
- Dicyclomine and Hyoscyamine
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Irritable Bowel Syndrome with Diarrhea (IBS-D) drugs are medications used to treat IBS-D. These drugs work by relieving the symptoms of IBS-D, including diarrhea.
Some of the major companies in the irritable bowel syndrome with diarrhea (ibs-d) drugs market are Astellas Pharmaceuticals, Actavis, Pfizer, GlaxoSmithKline, Salix Pharmaceuticals Ltd, AstraZenenca.
The irritable bowel syndrome with diarrhea (ibs-d) drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market - Supply Chain
4.5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast
4.5.1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Absolute $ Opportunity
5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
5.3.1. Preface
5.3.2. Eluxadoline
5.3.3. Alosetron
5.3.4. Rifaximin
5.3.5. Loperamide
5.3.6. Diphenoxylate + Atropine
5.3.7. Dicyclomine and Hyoscyamine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share Forecast, 2019-2026
9. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
9.7.1. Preface
9.7.2. Eluxadoline
9.7.3. Alosetron
9.7.4. Rifaximin
9.7.5. Loperamide
9.7.6. Diphenoxylate + Atropine
9.7.7. Dicyclomine and Hyoscyamine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share Forecast, 2019-2026
10. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
10.7.1. Preface
10.7.2. Eluxadoline
10.7.3. Alosetron
10.7.4. Rifaximin
10.7.5. Loperamide
10.7.6. Diphenoxylate + Atropine
10.7.7. Dicyclomine and Hyoscyamine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share Forecast, 2019-2026
11. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Irritable Bowel Sndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
11.7.1. Preface
11.7.2. Eluxadoline
11.7.3. Alosetron
11.7.4. Rifaximin
11.7.5. Loperamide
11.7.6. Diphenoxylate + Atropine
11.7.7. Dicyclomine and Hyoscyamine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share, 2019-2026
12. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
12.7.1. Preface
12.7.2. Eluxadoline
12.7.3. Alosetron
12.7.4. Rifaximin
12.7.5. Loperamide
12.7.6. Diphenoxylate + Atropine
12.7.7. Dicyclomine and Hyoscyamine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share, 2019-2026
13. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Volume Forecast by Type
13.7.1. Preface
13.7.2. Eluxadoline
13.7.3. Alosetron
13.7.4. Rifaximin
13.7.5. Loperamide
13.7.6. Diphenoxylate + Atropine
13.7.7. Dicyclomine and Hyoscyamine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Market Share Analysis
14.2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors and Customers
14.3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Actavis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Salix Pharmaceuticals Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AstraZenenca
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1.
